(Q24202004)

3

0 references

Andrew Prendergast

2

object named as

Andrew Prendergast

0 references

Diana M Gibb

5

object named as

Diana Gibb

0 references

Martina Penazzato

1

object named as

Martina Penazzato

0 references

author name string

Mark Cotton

Cochrane Database of Systematic Reviews

4

0 references

publication date

11 July 2012

0 references

published in

0 references

cites work

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Antiretroviral treatment for children with peripartum nevirapine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

A trial of three antiretroviral regimens in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Efficacy of highly active antiretroviral therapy in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021

Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021

Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021

Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021

Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB3

7 January 2021